10-Q: Hyperion DeFi Secures Capital, Pivots to Crypto Treasury

Hyperion DeFi reports a strategic pivot to a HYPE digital token treasury, significant capital raise, and debt restructuring, alongside ongoing ophthalmic device development, despite continued net losses.

Summary

• Hyperion DeFi, formerly Eyenovia, Inc., completed a 1-for-80 reverse stock split on January 31, 2025.
• The company reported a net loss of $12.17 million for the six months ended June 30, 2025, a significant improvement from $21.98 million in the same period of 2024.
• Cash used in operating activities for the six months ended June 30, 2025, was $7.89 million, down from $18.07 million in the prior year.
• Cash and cash equivalents increased to $7.53 million as of June 30, 2025, from $2.12 million at December 31, 2024.
• The company acquired $45.5 million in HYPE digital tokens in June 2025 as a long-term strategic treasury asset.
• Working capital deficit substantially improved to $0.92 million as of June 30, 2025, from $13.28 million at December 31, 2024.
• Stockholders' equity turned positive to $37.36 million as of June 30, 2025, from a deficit of $13.10 million at December 31, 2024.
• A private placement closed on June 20, 2025, raising $50 million in gross proceeds.
• The Avenue Loan maturity was extended to July 1, 2028, the interest rate reduced from 12% to 8%, and an interest-only period was established until January 31, 2027.
• The company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement, reporting $37.4 million in equity as of June 30, 2025, after receiving a non-compliance notice on April 29, 2025.
• Development of the Optejet User Filled Device (UFD) continues, with anticipated FDA registration this year.

Sentiment

Score: 6

Explanation: The company successfully executed a significant capital raise and debt restructuring, substantially improving its balance sheet and addressing immediate Nasdaq compliance issues. The strategic pivot to a HYPE digital token treasury offers a new growth vector. However, the company continues to incur net losses, operates with a working capital deficit, and faces substantial doubt about its going concern status, necessitating further capital raises or HYPE sales. Significant risks are associated with the volatility and regulatory uncertainty of digital assets, and material weaknesses in internal controls were identified.

Positives

• Stockholders' equity significantly improved to $37.36 million from a $13.10 million deficit, demonstrating a stronger balance sheet.
• Successfully completed a private placement, raising $50 million in gross proceeds, bolstering capital reserves.
• Net loss for the six months ended June 30, 2025, decreased by 44.6% to $12.17 million from $21.98 million in the prior year period.
• Cash and cash equivalents increased to $7.53 million, providing enhanced liquidity.
• Working capital deficit was substantially reduced to $0.92 million from $13.28 million, indicating improved short-term financial health.
• Renegotiated the Avenue Loan, extending maturity to July 1, 2028, reducing the interest rate to 8%, and establishing an interest-only period until January 31, 2027, easing debt service obligations.
• Acquired $45.5 million in HYPE digital tokens, establishing a strategic treasury asset with potential for yield generation.
• Anticipates FDA registration of the Optejet User Filled Device this year, progressing its ophthalmic technology segment.
• Believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.

Negatives

• Continues to report a net loss of $12.17 million for the six months ended June 30, 2025.
• Maintains a working capital deficit of $0.92 million, indicating ongoing short-term liquidity challenges.
• Management identified substantial doubt about the company's ability to continue as a going concern within the next 12 months, necessitating further financing or HYPE token sales.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in accounting for complex, non-routine transactions and ROU asset impairments.
• Selling, general, and administrative expenses increased by 36% to $10.1 million for the six months ended June 30, 2025, primarily due to non-cash stock-based compensation and professional fees related to strategic evaluations.
• Significant cash outflow of $45.5 million for HYPE digital token purchases in investing activities.

Risks

• HYPE is a highly volatile asset, and fluctuations in its price may significantly influence financial results and the market price of listed securities.
• HYPE and other digital assets are novel and subject to significant legal and regulatory uncertainty, which could adversely impact their price or the company's ability to own or transfer them.
• The HYPE treasury strategy subjects the company to enhanced regulatory oversight, including potential scrutiny under money services, money transmitter licensing, and commodity/securities laws.
• There is a risk that HYPE may be classified as a security, which would subject the company to additional regulation (e.g., Investment Company Act of 1940) and could make current business segments impractical.
• Disruption or unanticipated difficulties in the peer-to-peer Hyperliquid network could negatively impact the value of HYPE and transaction processing.
• Risks related to the custody of HYPE include loss or destruction of private keys, cyberattacks, smart contract vulnerabilities, and potential treatment as an unsecured creditor in custodian insolvency.
• Historical financial statements do not reflect the potential variability in earnings from HYPE holdings, leading to significant volatility due to fair value accounting.
• The company could become subject to the corporate alternative minimum tax (CAMT) under the Inflation Reduction Act of 2022 due to unrealized HYPE gains.
• The unregulated nature and lack of transparency of many HYPE trading venues may lead to fraud, security failures, or operational problems, adversely affecting HYPE value.
• Concentration of assets in HYPE holdings limits risk mitigation compared to a diversified portfolio.
• The emergence or growth of other digital assets could negatively impact the price of HYPE.
• Delisting from Nasdaq could prevent the company from maintaining an active, liquid, and orderly trading market for its common stock and adversely impact its ability to consummate strategic transactions.
• Geopolitical conflicts (Russia-Ukraine, Middle East, India-Pakistan) could affect the price of materials used in the manufacture of the product platform.

Future Outlook

The company anticipates reducing operating expenses upon the expected FDA registration of its Optejet User Filled Device this year. Management plans to raise additional funds through future financings and, if necessary, sell HYPE digital tokens to fund operations, expecting these actions to alleviate substantial doubt about its ability to continue as a going concern for the next year. The new strategy aims to provide shareholders with compounding exposure to HYPE through native staking yield and additional revenues from on-chain utility. The company expects to generate yield by deploying HYPE into the HyperEVM for lending and liquidity provisioning, which will be compounded into its overall HYPE acquisition strategy. It believes this approach will accelerate the growth of the Hyperliquid ecosystem, drive platform usage, increase protocol value, and strengthen its long-term position.

Management Comments

• Hyperion DeFi is working to provide its shareholders with simplified exposure to the Hyperliquid ecosystem, which we believe to be one of the fastest-growing, highest revenue-generating blockchains in the world.
• At the same time, the Company continues to execute on its planned completion of the development and registration of its Optejet ophthalmic liquid delivery device.
• Management's plan is expected to alleviate the substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.
• By prudently building and deploying a treasury of HYPE, we believe that we can rapidly accelerate the growth of the Hyperliquid ecosystem and further its adoption, potentially creating a powerful flywheel effect that may drive platform usage, increase protocol value and strengthen the long-term position of both the Hyperliquid ecosystem and the Company.
• We anticipate registering the second generation of the Optejet UFD as a liquid drug delivery device, based on our experience with MydCombi.
• We have submitted a plan to regain compliance with the Nasdaq Listing Rules, which we believe should be acceptable to Nasdaq, although no assurance can be given.
• We believe that the financial statements in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods presented, in conformity with U.S. GAAP.

Industry Context

The company is undergoing a significant strategic pivot, transitioning from a pure ophthalmic technology focus to a hybrid model that includes a substantial investment in the decentralized finance (DeFi) sector through its HYPE digital token treasury. This reflects a broader industry trend of companies exploring digital assets and blockchain technology for treasury management and new revenue streams, positioning Hyperion DeFi within the rapidly evolving and highly volatile DeFi market. Concurrently, the company continues its development in the medical device and pharmaceutical delivery industry with its Optejet device, a sector characterized by stringent regulatory requirements and a focus on patient outcomes. The dual strategy places the company at the intersection of two distinct and dynamic industries, each with unique growth drivers and regulatory landscapes.

Comparison to Industry Standards

• For the Optejet User Filled Device (UFD), the company highlights a 98% successful administration rate upon first attempt, which it compares favorably to the established rate of approximately 50% reported with traditional eye drops, indicating a significant improvement in delivery efficacy.
• The Optejet UFD delivers a physiologically appropriate volume of medication (7 to 10 microliters), which is approximately one-fifth of the 35 to 50 microliter dose typically delivered by a single eye drop, suggesting enhanced safety and tolerability compared to conventional methods.
• For its HYPE treasury strategy, the company describes the Hyperliquid blockchain as a Layer-1 network designed for high-frequency, transparent trading, operating with block times of approximately 70 milliseconds and supporting up to 200,000 transactions per second. While these are competitive performance metrics for decentralized exchanges and Layer-1 blockchains, the filing does not provide specific comparisons to named competitor platforms or their performance benchmarks within the broader DeFi industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• May become involved in legal proceedings, claims, and assessments arising in the ordinary course of business.

Stakeholder Impact

• Shareholders: Experience significant potential dilution from the conversion of preferred stock and exercise of warrants, but benefit from improved financial stability, reduced net losses, and a new strategic direction with potential for high growth. Face risks from digital asset volatility and regulatory uncertainty.
• Employees: Affected by a reduction in force (COO termination) but also benefit from ongoing equity compensation plans and the potential for growth in the new strategic direction.
• Creditors (Avenue Lenders): Benefit from warrants issued as compensation and a more stable repayment schedule due to extended maturity, reduced interest rates, and an interest-only period on the Avenue Loan.
• Customers/Patients (Optejet): May benefit from the continued development and anticipated FDA registration of the Optejet User Filled Device, which promises enhanced safety, tolerability, and compliance for ophthalmic treatments.
• Hyperliquid Ecosystem: The company's HYPE treasury strategy aims to accelerate the growth and adoption of the Hyperliquid ecosystem, potentially increasing its usage and value.

Next Steps

• Complete the development and registration of the Optejet User Filled Device with the FDA.
• Continue to build and deploy a treasury of HYPE digital tokens.
• Engage in HYPE staking, restaking, or other permitted activities using smart contracts or decentralized applications to generate income.
• Potentially create unique financial products built around the demand for Hyperliquid network benefits.
• Raise additional funds through future financings to support operations.
• Potentially sell HYPE digital tokens to fund operations if necessary.
• Address identified material weaknesses in disclosure controls and procedures.
• Review the Amended and Restated Non-Employee Director Compensation Policy in the first quarter of 2026.

Key Dates

Recommendation

The company has made significant strides in improving its financial stability through a substantial capital raise and debt restructuring, which has addressed immediate liquidity and Nasdaq compliance concerns. The strategic pivot to a HYPE digital asset treasury offers a high-growth, albeit high-risk, new direction. However, the company still faces a going concern risk, continues to report net losses, and has identified material weaknesses in its internal controls. The inherent volatility and regulatory uncertainty surrounding digital assets, coupled with potential dilution from convertible preferred stock and warrants, present considerable risks. A 'Hold' recommendation reflects the improved financial position and potential upside from the new strategy, balanced against the significant operational and market risks that warrant caution.

Keywords

Hyperion DeFi, HYPE token, Hyperliquid, Optejet, ophthalmic technology, digital assets, cryptocurrency, SEC filing, 10-Q, financial results, capital raise, debt restructuring, Nasdaq compliance, corporate governance, risk management